KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CRISPR Therapeutics AG (CRSP) Income from Continuing Operations (2016 - 2025)

CRISPR Therapeutics AG (CRSP) has disclosed Income from Continuing Operations for 11 consecutive years, with 163160000.0 as the latest value for Q4 2025.

  • Quarterly Income from Continuing Operations fell 106.46% to 163160000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 614127000.0 through Dec 2025, down 50.53% year-over-year, with the annual reading at 614126000.0 for FY2025, 50.53% down from the prior year.
  • Income from Continuing Operations hit 163160000.0 in Q4 2025 for CRISPR Therapeutics AG, down from 106422000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 759268000.0 in Q2 2021 to a low of 514485000.0 in Q4 2021.
  • Historically, Income from Continuing Operations has averaged 91184700.0 across 5 years, with a median of 114877500.0 in 2021.
  • Biggest YoY gain for Income from Continuing Operations was 1053.18% in 2021; the steepest drop was 306.54% in 2021.
  • Year by year, Income from Continuing Operations stood at 514485000.0 in 2021, then soared by 78.05% to 112906000.0 in 2022, then skyrocketed by 179.17% to 89392000.0 in 2023, then crashed by 188.41% to 79027000.0 in 2024, then tumbled by 106.46% to 163160000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for CRSP at 163160000.0 in Q4 2025, 106422000.0 in Q3 2025, and 208549000.0 in Q2 2025.